Celebrating 2 years! Big clinical milestones this year: initiation of our Ph2b BUOY‑1 trial of GlyphAllo in MDD & positive proof-of-concept Ph1 topline data for GlyphAgo. Proud of our progress & what’s ahead as we make a difference for those struggling w/ #depression & #anxiety.

Positive Ph1 proof‑of‑concept topline results for GlyphAgo: 10x lower PK variability & 6.8x increase in bioavailability–exceeding our 2x target projected to mitigate liver exposure, a limitation that previously held back agomelatine's clinical use: bit.ly/3PBOkWV

Proud of the work of our Seaport team & collaborators published today in @ScienceTM. This ~13 page peer reviewed paper is the first comprehensive data disclosure of our GlyphAllo™ program from discovery through initial human proof‑of‑concept

Seaport Therapeutics@seaporttx.bsky.social · 7mo ago

New paper in Science Translational Medicine features GlyphAllo as first triglyceride-mimetic prodrug to achieve therapeutically relevant drug levels in humans & further validates Glyph platform to effectively enable oral dosing. Paper: tinyurl.com/2mff276w Release: tinyurl.com/5hdenetm

Seaport & Monash awarded up to $15M from ARPA‑H to advance GlyphCele™, supporting broader potential of Glyph platform to address diseases linked to gut lymphatic dysfunction (metabolic disease & pancreatic cancer) to reach patients beyond #CNS bit.ly/3MDnSLq

Iranian women celebrating

Co‑founder & Board Chair Dr Steve Paul joined BioCentury's podcast to discuss the past, present & future of neuropsychiatric drug development – from the depression space to potential of psychedelics - & what we’re building at Seaport w/our Glyph platform: bit.ly/4r2gRCy

Serendipity drives discovery in psychiatry, engineering gets it across the line, says Steve Paul

With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery...

bit.ly

Sounds “cute” as in puppies talking to each other but quite ominous and will soon be too late to shut down. AI bots are organizing, agreeing on how they interact in their own language, identifying “human in the loop” vulnerabilities (“my human clicks approve without reading”) lnkd.in/eNSbNhp3

Why is nobody talking about Iran?

DAY 14 of #DigitalBlackoutlran #IranMassacre #IranRevolution2026 #FreeIran

Co-founder & CEO @daphnezohar.bsky.social presented at #JPM26 sharing our recent progress & path forward as we tackle some of the biggest medical problems our population is facing today. Co-founders Steve Paul (Chair) & Michael Chen (CSO) joined for Q&A. #depression #anxiety #neuropsychiatry

Our Co-founder & CEO, @daphnezohar.bsky.social, will present at #JPM26 on Jan. 12 at 9:30AM PT. She’ll be joined by Steve Paul, M.D., Co-founder & Chair & Michael Chen, Ph.D., Co-founder & CSO, during the Q&A portion of the presentation. bit.ly/3NsW6kt

Ok here it is - out of 44 FDA approvals this year, 31 are small molecules (70%), 26 of those are oral drugs (84%), 22 of them are chiral (71%). This is the largest number and percentage of chiral FDA approved molecules in a single year. Fitusiran is not a small molecule, bonus.

Today Co-Founder & Board Chair Dr. Steve Paul joins Technology Innovation Studio’s Breakthrough Biotech Builders fireside chat on his role in the dev of CNS blockbusters Zyprexa®, Cymbalta® and Cobenfy™ (KarXT) which originated at PureTech (founded/led by @daphnezohar.bsky.social) luma.com/5rfgvqfd

Breakthrough Biotech Builders: Session with Steve Paul · Luma

This discussion would be a private gathering designed to foster high-level dialogue and genuine connections in the area of biotech leadership. We hope that…

luma.com

Available on Spotify, podcasts and YouTube now in addition to Spaces

Biotech Hangout@biotechhangout.bsky.social · 12mo ago

#BiotechHangout John Maraganore, Yaron Werber, Ami Fadia, Allison DeAngelis, Drew Armstrong on policy: MAHA summit, Pazdur to CDER, ‘plausible mechanism pathway’, deals: $DAWN/$MRSN, $PFE/$MTSR, Lundbeck/$AVDL, $MRK/$CDTX, data: $ALKS, $NBIX, $COGT, $KRRO, $CRSP, James Watson passing: bit.ly/4i0C6Rt

Wear pink Tues Jan 13th at #JPM26 to recognize impact of women leaders & allies in bio. Wear a pink shirt, tie or socks if you don’t own a pink blazer. We had an incredible turnout at inaugural event at #JPM25 w/ pink visible throughout the streets of SF. Join group pic at 4pm #BiotechCEOSisterhood

Mark your calendars! #BiotechHangout & @biotechtv.bsky.social will be back at #JPM26. Join us at Persona to meet up with biotech friends IRL on Tuesday, January 13 from 7-10pm. Interested in sponsoring? Email team@biotechhangout.com for more information. Additional registration information to come.

Members of our exec team joined Fierce Biotech’s #Fierce15 awards to celebrate our recognition, honoring our team's work developing new medicines for #depression & #anxiety. It's also a reflection of the strong momentum & growth since our launch last year. bit.ly/3VSOQQ7

We convened top neuropsych experts, sell-side analysts, investors, & biopharma leaders for a unique roundtable discussion on the opportunities & excitement in #neuropsychiatry & what’s next as #MentalHealth conditions continue to impact millions globally. See below for some takeaways

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐓𝐨𝐮𝐫: BiotechTV visited the new offices of @seaporttx.bsky.social today and was given a tour by Founder & CEO @daphnezohar.bsky.social

For @biotechtv.bsky.social's Biotech CEO Sisterhood series, our CEO @daphnezohar.bsky.social spoke to Sophie Kornowski on her journey leading Boston Pharmaceuticals to a $2B deal w/ GSK. Check this out for insights from both leaders on dealmaking, leadership strategies & mentorship: bit.ly/4m55kzG

Biotech CEO Sisterhood: As CEO, Sophie Kornowski sold Boston Pharmaceuticals to GSK earlier this year for up to $2 billion. She shares her thoughts on the biopharma business and leadership

Interviewed by Sisterhood editorial board member Daphne Zohar, Sophie Kornowski shares her keys to creating great assets, commercialization, partnerships, and, ultimately, executing a successful deal ...

bit.ly

Pleased to announce the first patient has been dosed in our Ph2b BUOY-1 study of GlyphAllo™ (SPT-300) in #MDD w/ or w/o anxious distress, an important milestone for Seaport’s pipeline that brings us closer to a potential new treatment for patients w/ MDD: bit.ly/3Uhn3YB

#BiotechHangout Eric Schmidt, Brad Loncar, Tim Opler, Tess Cameron on M&A: $MRK/$VRNA, $ABBV/Capstan, biotech takeouts, M&A wave, pharma’s $150B in LOE, plus Trump’s BBB/tariffs, $XBI & MFN, FDA’s CRL disclosures, $CAPR, $KALV, $PROK, obesity trends, $RARE/$MREO, $ABBV/Ichnos: bit.ly/3TuICVp

The Seaport crew kicked off summer with a fun gathering! Great opportunity to connect out of the office, strengthening our mission to develop life-changing medicines for #neuropsychiatric disorders. Looking forward to more moments together and progress towards transforming lives!

As #MentalHealthMonth closes, we welcomed a @namicommunicate.bsky.social patient representative to share his journey w/ mental health conditions. His story inspires our work at Seaport to help those struggling & develop new medicines for #depression & #anxiety. More: www.nami.org

#BiotechHangout: Chris Garabedian, Josh Schimmer, Nina Kjellson, Mike Yee, Tim Opler on market sentiment – where is the M&A?, FDA/CBER, wind downs vs reverse mergers, policy: #MAHA & COVID vaccine, $REGN/23andMe, data: $RCKT, psychedelics, $PRTA, $SPRO/$GSK, $GILD, $SMMT, #ASCO & more bit.ly/4dCFzDT

Two people were shot and killed outside a Jewish LGBTQ event in D.C.

Man, woman shot and killed in front of Capital Jewish Museum in DC

A man and woman were shot and killed in front of the Capital Jewish Museum in Northwest D.C. Wednesday evening. The shooting took place in the area of 3rd and F streets in Northwest — in front of the ...

nbcwashington.com

This #MentalHealthMonth, we joined @namicommunicate.bsky.social's annual #NAMIWalks to combat stigma & promote mental health awareness. We stand with those affected by mental illness & are dedicated to developing new medicines for #depression & #anxiety. More about NAMI www.nami.org

#BiotechHangout: Sam Fazeli, John Maraganore, Nina Kjellson, Matt Gline on MFN: 30-day ultimatum, 180 days negotiation, reimportation, ex-US prices, DTC, Roche, $SNY, plus: budget reconciliation, IRA, $RXRX, Galapagos, $CTMX, $GSK buys Boston, $GSK/iTeos, $NVO CEO, RNA deals: bit.ly/3S3vhTh

Seems like Bluesky is losing momentum? Wouldn’t mind having one less place to check/post. Curious to hear from others

Important provisions added to reconciliation bills would be positive for bio if passed: ORPHAN Cures Act included, amend IRA PBM reforms delinking compensation from list price, increasing transparency & banning spread pricing in Medicaid Tax fix to allow for immediate deduction of R&D costs